Kenneth Pitzer Net Worth

Kenneth Pitzer biography

Dr. Kenneth R. Pitzer serves as Senior Vice President - Product Strategy and Commercial Planning of the Company. Previously, Dr. Pitzer has served as our Senior Vice President, Product Strategy and Commercial Planning since March 2016. Previously, Dr. Pitzer was Vice President, Strategic and Commercial Planning since he joined Theravance Biopharma in October 2014 from Innoviva, where he held the position of Vice President, Strategic and Commercial Planning since January 2008. Dr. Pitzer joined Innoviva in 2002 as Director, New Product Planning, and held various positions in the Commercial Development Department before being promoted to Vice President, Strategic and Commercial Planning in January 2008. Prior to joining Innoviva Dr. Pitzer worked at Lederle Laboratories, a pharmaceutical manufacturing company, as Marketing Manager from 1989 to 1995 and then at Cygnus, Inc., a Management. Dr. Pitzer earned a Doctor of Veterinary Medicine degree from The Ohio State University in 1987 and an M.B.A. from Carnegie-Mellon University in 1989.

How old is Kenneth Pitzer?

Kenneth Pitzer is 56, he's been the Senior Vice President - Product Strategy and Commercial Planning of Theravance Biopharma Inc since 2016. There are 15 older and 11 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.

What's Kenneth Pitzer's mailing address?

Kenneth's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Theravance Biopharma Inc

Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, és Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.

What does Theravance Biopharma Inc do?

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Theravance Biopharma Inc executives and stock owners

Theravance Biopharma Inc executives and other stock owners filed with the SEC include:

• Rick Winningham,
  Chairman of the Board, Chief Executive Officer
• Andrew Hindman,
  Chief Financial Officer, Senior Vice President
• Bradford Shafer,
  Executive Vice President, General Counsel, Secretary
• Brett Haumann,
  Senior Vice President, Clinical Development and Chief Medical Officer
• Frank Pasqualone,
  Senior Vice President and Chief Commercial Operations Officer
• Philip Worboys,
  Senior Vice President - Research and Translational Science
• Rick E. Winningham M.B.A.,
  Chairman & CEO
• Andrew Asa Hindman,
  Sr. VP & CFO
• Bradford J. Shafer,
  Exec. VP, Gen. Counsel & Sec.
• Andrew Asa Hindman M.B.A,
  Sr. VP & CFO
• Rhonda F. Farnum,
  Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs
• William Young,
  Lead Independent Director
• Burton Malkiel,
  Independent Director
• Donal O'Connor,
  Independent Director
• Dean Mitchell,
  Independent Director
• Susan Molineaux,
  Independent Director
• Eran Broshy,
  Independent Director
• Laurie Alsup,
  Independent Director
• George Whitesides,
  Independent Director
• Robert Gunderson,
  Director
• Deepika Pakianathan,
  Independent Director
• Vijay Sabesan,
  Senior Vice President - Technical Operations
• Kenneth Pitzer,
  Senior Vice President - Product Strategy and Commercial Planning
• Ann Brady,
  President - Theravance Biopharma Ireland Limited
• Dr. Ann B. Brady Ph.D.,
  Pres of Theravance Biopharma Ireland Limited
• Dr. Richard A. Graham Ph.D.,
  Sr. VP of Devel.
• Daniel Long,
  Head of Medicinal Chemistry
• Dr. Kenneth R. Pitzer,
  Sr. VP of Product Strategy & Commercial Planning
• Dr. Phillip D. Worboys,
  Sr. VP of Research & Translational Science
• Dennis O. Driver,
  Sr. VP of HR, Organizational and Leadership Devel.
• Gail B. Cohen,
  VP of Corp. Communications & Investor Relations
• Jeremy T Grant,
  
• Renee D Gala,
  VP-Finance
• Peter S Ringrose,
  Director
• Junning Lee,
  Sr. VP, Technical Operations
• Sharathchandra S Hegde,
  SVP, Research
• Henrietta Fore,
  Director
• Shehnaaz Suliman,
  SVP, Corp Dev & Strategy
• Jeffrey David Jonker,
  Senior VP, Corp. & Bus. Dev.
• Michael G Atieh,
  Director
• Leonard M Blum,
  Sr VP, Chief Comm. Officer
• Inc. Innoviva,,
  10% owner
• Mathai Mammen,
  SVP, Research & Early Clin Dev
• Rhonda Farnum,
  SVP, COMM & MEDICAL AFFAIRS
• Richard A Graham,
  SVP, RESEARCH & DEVELOPMENT
• Plc Gsk,
  
• Aziz Sawaf,
  SVP & CHIEF FINANCIAL OFFICER
• Brett A. Grimaud,
  SVP, GEN COUNSEL AND SECRETARY
• Susannah Gray,
  
• Aine Miller,
  SVP, DEV & HEAD OF IRE OFFICE
• Eli Samaha,
  10% owner